• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Carboxylic acid derivatives Carboxylic acid amides

Professional Introduction to 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide (CAS No. 1006484-06-5)

4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide is a significant compound in the field of pharmaceutical chemistry, exhibiting a unique molecular structure that has garnered considerable attention from researchers worldwide. This compound, identified by its CAS number 1006484-06-5, belongs to the pyrazole class of heterocyclic compounds, which are widely recognized for their diverse biological activities and potential therapeutic applications.

The molecular formula of 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide is C?H??N?O, reflecting its composition of carbon, hydrogen, nitrogen, and oxygen atoms. The presence of multiple functional groups, including an amino group at the 4-position and a carboxamide group at the 3-position, contributes to its complex reactivity and biological interactions. These features make it a valuable scaffold for the development of novel pharmaceutical agents.

In recent years, there has been a surge in research focused on pyrazole derivatives due to their broad spectrum of biological activities. Studies have demonstrated that compounds within this class exhibit properties such as anti-inflammatory, antimicrobial, and anticancer effects. Specifically, 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide has shown promise in preclinical studies as a potential lead compound for further drug development.

The synthesis of 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide involves a multi-step process that requires precise control over reaction conditions and reagent selection. The introduction of the amino and carboxamide groups necessitates careful optimization to ensure high yield and purity. Advanced synthetic methodologies, such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, have been employed to enhance the efficiency of the synthesis process.

One of the most compelling aspects of 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide is its potential as a pharmacophore in drug design. The pyrazole core provides a rigid framework that can be modified to target specific biological pathways. Researchers have leveraged this flexibility to develop derivatives with enhanced potency and selectivity. For instance, modifications at the 5-position of the pyrazole ring have been explored to improve binding affinity to biological targets.

The pharmacological profile of 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide has been extensively studied in vitro and in vivo. Initial investigations have revealed its ability to modulate enzymes and receptors involved in inflammation and cancer progression. These findings have spurred further research into its mechanisms of action and potential therapeutic applications. Preclinical studies have demonstrated its efficacy in models of acute inflammation and tumor growth, suggesting its viability as a candidate for clinical trials.

The development of novel drug candidates relies heavily on robust analytical techniques to characterize their chemical properties and biological activity. High-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) are commonly employed methods for analyzing 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide. These techniques provide detailed information about its purity, molecular structure, and interaction with biological targets.

In conclusion, 4-amino-N-ethyl-1-methyl-1H-pyrazole-3-carboxamide (CAS No. 1006484-06-5) represents a promising compound in pharmaceutical research due to its unique structural features and biological activities. Its synthesis presents challenges that require advanced chemical methodologies, but its potential as a lead compound for drug development makes it an attractive target for further investigation. As research continues to uncover new applications for pyrazole derivatives, compounds like this are poised to play a crucial role in the next generation of therapeutic agents.

• 1004194-71-1(4-Amino-1-ethyl-1H-pyrazole-3-carboxylic acid isobutyl-amide)
• 906087-57-8(4-amino-N-cyclopentyl-1-methyl-1H-pyrazole-3-carboxamide)
• 1185005-86-0(4-Amino-1-ethyl-1 H -pyrazole-3-carboxylic acid propylamide; hydrochloride)
• 1006485-32-0(4-amino-N,1-diethyl-1H-pyrazole-3-carboxamide)
• 1001500-16-8(4-amino-1-ethyl-N-propyl-1H-pyrazole-3-carboxamide)
• 1201935-77-4(4-Amino-N,N,1-trimethylpyrazole-3-carboxamide)
• 1004644-20-5(4-Amino-1-ethyl-1H-pyrazole-3-carboxylic acid isopropylamide)
• 1415147-85-1(4-amino-1-methyl-N-(propan-2-yl)-1H-pyrazole-3-carboxamide)
• 1185469-35-5(4-Amino-1-methyl-1 H -pyrazole-3-carboxylic acid methylamide; hydrochloride)
• 1001500-41-9(4-Amino-N,1-dimethyl-1H-pyrazole-3-carboxamide)